Medpace (MEDP) Q2 2026: Net Bookings Jump 28% as Oncology Mix Reclaims Pipeline
Medpace delivered a record quarter for net bookings, up 28% year over year, with a decisive shift back to oncology-led demand and a notable reduction in cancellations that helped drive backlog stability. Management’s focus on disciplined backlog gating and operational execution is recalibrating the company’s growth trajectory for 2027, while evolving mix and funding breadth signal a more balanced pipeline ahead. Investors should monitor the transition in therapeutic area mix and its impact on conversion rates and future revenue recognition.
Summary
- Oncology Resurgence: Oncology programs now comprise over half of new bookings, signaling a major mix shift.
- Cancellations Tamed: Reduced cancellations drove a record net bookings quarter, stabilizing backlog outlook.
- Backlog Conversion in Focus: Tightened backlog gating and evolving project age will shape future revenue flow.
Business Overview
Medpace is a global contract research organization (CRO), providing clinical trial management and related services to pharmaceutical, biotech, and medical device companies. The company generates revenue by designing, running, and supporting clinical studies, primarily in late-stage (Phase II and III) development. Its major segments are defined by therapeutic area mix—recently dominated by cardiometabolic and oncology programs—and by the lifecycle stage of projects in its backlog and pre-backlog pipelines.
Performance Analysis
Medpace posted double-digit top-line growth, with revenue up 17.2% year over year, and EBITDA expanding 17.6%. Net income outpaced EBITDA growth, reflecting a lower effective tax rate and higher interest income. The EBITDA margin remained stable at 21.7%, with year-to-date margin flat as lower employee costs offset higher reimbursables, a pass-through cost structure where certain expenses are billed directly to clients.
Net new business awards surged 28.2% year over year, reaching $795.7 million and producing a book-to-bill ratio of 1.13. Backlog ended the quarter at approximately $3 billion, up 4.9%, with $1.96 billion projected to convert to revenue over the next 12 months. Operating cash flow was robust at $162 million, and share repurchases remained aggressive, with $294.7 million deployed in Q2 and $527 million authorization remaining. Customer concentration increased, with the top five clients now accounting for 31% of trailing twelve-month revenue.
- Oncology Drives Mix Shift: Oncology represented over half of Q2 bookings and award notifications, reversing last year’s cardiometabolic dominance.
- Backlog Conversion Rate Elevated: Backlog conversion hit 24.1%, above historical averages, due to tighter backlog gating and aging project mix.
- Cash Deployment Aggressive: Share repurchases continued at scale, signaling confidence in future cash generation and capital discipline.
Management highlighted that backlog conversion is less about therapeutic area “burn rates” and more about policy discipline and project age, suggesting future normalization as oncology regains share and new awards refresh the backlog profile.
Executive Commentary
"Cancellations were well-behaved and supported a record quarter for net bookings. RFPs were up sequentially and year over year, generating high quality opportunities. Initial award notifications remained solid, although they declined sequentially from a very strong Q1. Overall, the environment remains constructive and we are making good progress in positioning the business for 2027."
August Troendle, CEO
"Net new business awards entering backlog in the second quarter increased 28.2% from the prior year to $795.7 million, resulting in a 1.13 net book to build. Ending backlog as of June 30, 2026, is approximately $3 billion, an increase of 4.9% from the prior year. We project that approximately $1.96 billion of backlog will convert to revenue in the next 12 months."
Kevin Brady, CFO
Strategic Positioning
1. Oncology Regains Pipeline Dominance
Oncology programs now represent over half of both bookings and award notifications, indicating a major pivot from last year’s cardiometabolic-led growth. This shift is expected to persist, with management anticipating a return to historical mix as large metabolic awards roll off and oncology opportunities expand, potentially elongating average project duration and impacting future backlog conversion rates.
2. Backlog Gating and Conversion Discipline
Management has tightened backlog recognition policies, only including revenue with clear visibility past key interim decision points. This discipline, implemented in response to prior elevated cancellations, has temporarily elevated the backlog conversion rate, but is expected to normalize as project mix and age rebalance. This approach limits the risk of large, unexpected backlog reductions and aligns revenue recognition with program certainty.
3. Funding Environment and Opportunity Breadth
RFP activity and the quality of opportunities are both up, driven by broader biotech funding dispersal rather than concentration among a few large players. Management noted that more clients are coming to market with recent funding, accelerating decision-making and program starts, which supports a constructive outlook for gross bookings in the second half of 2026.
4. Cost Structure and Margin Management
Direct service costs and reimbursable expenses remain a key focus, with CFO guidance for these to trend toward 41–42% of revenue in the back half. Employee growth remains high single digits, with the majority in the U.S. and Asia-Pacific, including India, reflecting a blend of cost management and resource localization. Margin expansion is expected to be modest as headcount growth lags revenue growth.
5. Shareholder Returns and Capital Allocation
Share repurchases continue to be a core capital allocation lever, with nearly $300 million deployed in Q2 alone. Management’s willingness to return capital at this scale reflects strong cash flow generation and confidence in the durability of the business model, even as customer concentration rises and project mix evolves.
Key Considerations
This quarter marks a decisive transition in Medpace’s growth drivers and operational discipline. The company is navigating a shift from cardiometabolic to oncology-led bookings, while managing backlog recognition and conversion with heightened scrutiny. Investors should assess the underlying sustainability of net bookings growth, the implications of customer concentration, and the normalization path for backlog conversion rates.
Key Considerations:
- Therapeutic Mix Inversion: Oncology’s resurgence could extend project timelines and impact future revenue cadence.
- Backlog Conversion Sustainability: Elevated burn rates may revert as project mix and age rebalance, affecting near-term revenue visibility.
- Cancellations Remain Unpredictable: While Q2 saw improvement, management acknowledges limited visibility into future spikes.
- Customer Concentration Risk: Top five clients now account for nearly a third of revenue, heightening exposure to large program volatility.
- Capital Allocation Aggressiveness: Continued share repurchases signal confidence, but also limit cash flexibility if market conditions shift.
Risks
Key risks include potential spikes in cancellations, which management admits are inherently unpredictable and can materially impact bookings and backlog. Customer concentration exposes Medpace to program-specific volatility, especially as large metabolic programs roll off and oncology ramps. Normalization of backlog conversion rates as mix shifts could dampen revenue growth in future periods if not offset by sustained gross bookings momentum. Regulatory changes and competitive dynamics, especially in global trial execution, remain ongoing watchpoints.
Forward Outlook
For Q3 and Q4 2026, Medpace guided to:
- Revenue in the range of $2.805 billion to $2.885 billion for full-year 2026
- EBITDA of $618 million to $642 million for the year
For full-year 2026, management raised guidance:
- Net income expected between $494 million and $514 million
- Earnings per diluted share of $17.25 to $17.95
Management highlighted several factors that will shape the second half:
- Expectations for a ramp in gross and net bookings, contingent on cancellation trends
- Further normalization in backlog conversion as mix shifts and new awards refresh the pipeline
Takeaways
Medpace’s Q2 2026 results underscore a pivotal mix shift, with oncology regaining dominance and backlog discipline recalibrating future revenue recognition. Management’s focus on operational execution, risk gating, and capital returns positions the company for resilience, but investors must watch for normalization in conversion rates and any resurgence in cancellations as macro and funding environments evolve.
- Oncology Mix Shift: Oncology’s rise will likely extend average project duration and affect the pace of revenue realization as metabolic work fades.
- Backlog Policy Tightening: More disciplined backlog gating has temporarily boosted conversion but is expected to normalize, impacting revenue growth trends.
- Future Watchpoint: Track customer concentration and cancellation volatility, as both could materially influence bookings and margin trajectory in coming quarters.
Conclusion
Medpace enters the second half of 2026 with strong bookings momentum, a recalibrated therapeutic mix, and disciplined operational execution. The company’s ability to manage conversion normalization and customer concentration will determine the durability of its growth trajectory into 2027.
Industry Read-Through
Medpace’s results signal a broader CRO industry pivot, as oncology regains its historical share of clinical development activity and biotech funding becomes more widely distributed. The normalization of backlog conversion rates and the unpredictability of cancellations highlight the importance of disciplined backlog management and customer diversification for all CROs. Capital allocation trends, especially aggressive share repurchases, may become more prevalent as CROs seek to balance growth with shareholder returns in a maturing funding environment. Investors should expect similar mix and margin dynamics across the sector as project durations extend and pass-through costs fluctuate with therapeutic focus.